Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2022-05-31 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
VOLUNTARY CONVERSION TO DUAL-PRIMARY LISTING ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED
Regulatory Filings Classification · 95% confidence The document is an announcement from Zai Lab Limited regarding its voluntary conversion to a dual-primary listing on the Main Board of the Hong Kong Stock Exchange. It discusses background information, reasons and benefits of the primary conversion, compliance arrangements with HK Listing Rules, applications for waivers from strict compliance with HK Listing Rules, and related procedural details. The content is regulatory and compliance-focused, detailing corporate actions and listing status changes rather than financial results or reports. It is not a full financial report, earnings release, or management discussion. The document is lengthy (15,000 characters) and contains detailed information about the listing conversion process and regulatory compliance, which fits the profile of a Regulatory Filing (RNS) rather than a report publication announcement or other categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-05-31 English
DEFINITIVE ADDITIONAL MATERIALS/SUPPLEMENTAL ANNOUNCEMENT TO THE CIRCULAR FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a supplemental announcement related to the Annual General Meeting (AGM) of Zai Lab Limited. It specifically mentions definitive additional materials filed with the SEC as Schedule 14A, which is a proxy statement amendment. The content focuses on the change of format of the AGM to a virtual meeting due to COVID-19 restrictions, and it supplements the original proxy statement and notice of the AGM. There is no financial data or earnings information, nor is it a full annual report or interim report. The document is clearly related to AGM materials and proxy solicitation information. According to the filing definitions, proxy solicitation and information statements (including definitive proxy statements and supplemental materials) fall under the category "Proxy Solicitation & Information Statement (PSI)". The document length is over 11,000 characters, indicating it is not a brief announcement but substantive supplemental proxy materials. Therefore, the correct classification is PSI with high confidence.
2022-05-22 English
OVERSEAS REGULATORY ANNOUNCEMENT - FORM 10-Q
Interim / Quarterly Report Classification · 100% confidence The document is an announcement from Zai Lab Limited regarding the filing of their quarterly report on Form 10-Q for the quarter ended March 31, 2022, with the U.S. Securities and Exchange Commission. The text includes detailed financial statements, management discussion and analysis, risk factors, and other comprehensive financial information typical of a quarterly report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of the Form 10-Q label and detailed financial data confirms this is a quarterly report filing. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-05-11 English
ANNOUNCEMENT OF THE 2022 Q1 FINANCIAL RESULTS
Interim / Quarterly Report Classification · 95% confidence The document is titled 'ANNOUNCEMENT OF THE 2022 Q1 FINANCIAL RESULTS' and contains detailed financial results and corporate updates for the first quarter ended March 31, 2022. It includes extensive discussion of product highlights, clinical trial results, and anticipated milestones, which are typical contents of a quarterly financial report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement or notice. The presence of detailed financial and operational data for a quarter, along with management commentary, aligns with the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement of a report or a certification, so it should not be classified as RPA or RNS. Therefore, the appropriate classification is IR with high confidence.
2022-05-11 English
OVERSEAS REGULATORY ANNOUNCEMENT
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) by Zai Lab Limited. It registers additional shares under the company's 2017 Equity Incentive Plan. The document includes legal opinions, consents from independent auditors, and exhibits related to the registration of shares for issuance under an equity incentive plan. It is a regulatory filing related to securities registration and not a financial report, earnings release, or management discussion. The document is lengthy (over 14,000 characters) and contains the full registration statement, not just an announcement of a filing. The content fits the category of a regulatory filing related to compliance and securities registration rather than any other specific report type. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-05-10 English
OVERSEAS REGULATORY ANNOUNCEMENT - NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS
Proxy Solicitation & Information Statement Classification · 95% confidence The document is an announcement by Zai Lab Limited regarding the availability of proxy materials for the 2022 annual general meeting (AGM) of shareholders. It references a Schedule 14A filing with the SEC, which is a Proxy Statement or related materials. The text includes detailed voting items for the AGM, such as election of directors, approval of equity incentive plans, auditor appointment, and other shareholder resolutions. The document is not the proxy statement itself but additional definitive materials related to the proxy statement. It is not a full annual report, earnings release, or other financial report. The content fits the category of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings. The document length (8752 characters) and detailed voting proposals confirm it is substantive proxy solicitation material rather than a brief announcement or a report publication announcement.
2022-05-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.